There is an observational result that the eight core targets (CCL2, CTLA4, CXCL8, ICAM1, IL10, IL17A, IL1B, and IL2) overlapped among AD, AR, and AA were the therapeutic targets with the most potential against AM. This evidence concerns the gene ICAM1 and acute myeloblastic leukemia with maturation.